Home Blog Page 875

Jo Malone London introduces Georgia May and Lizzy Jagger as global brand ambassadors for English Pear

By
Advertorial Desk
-

LONDON, March 2, 2026 /PRNewswire/ — The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger. Hailing from rock and roll roots, Georgia May and Lizzy have unique individual styles and personalities, reflected in their unique choice of scents. English Pear & Freesia and English Pear & Sweet Pea offer two takes on the perfect pear, both featuring this timeless, quintessential Jo Malone London ingredient.

The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger.
The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger.

Georgia May

Jagger Georgia May began modelling at a young age, featuring in campaigns for a variety of global beauty and fashion brands. She launched her own skincare brand MAY Botanicals in 2023. She co-owns hair dye brand Bleach London and is the Wellbeing Ambassador for the British Beauty Council.

Lizzy Jagger

Lizzy first appeared on the catwalk in 1998 and has been modelling ever since, representing many designers at fashion weeks and featuring in campaigns for global brands. She is an advocate for women’s rights and worked on the award-winning documentary Equal Means Equal with Kamala Lopez, pushing for Women’s Equality Day to become Women’s Equality Week.

The campaign

Experience the sunlit orchard. Sister scents, one bond and an English pear in every bottle.

English Pear & Freesia: a cult classic

Orchards steeped in golden sunshine, warming the russet curves of luscious pears. The sensuous freshness of the just-ripe fruit wrapped in elegant white freesias, enhanced with rose and rooted in patchouli.

Top: Williams Pear

Heart: Freesia

Base: Patchouli

‘I love it because it’s classic and elegant. I feel I can reach for it every day and wear it anywhere. It’s really timeless’—Georgia May Jagger

English Pear & Sweet Pea: a new classic

Sun-warmed orchards spring to life as tempting green pears fill the branches. The luscious fruits enveloped in softly scented pastel sweet peas, nestled on a base of powdery white musk.

Top: Williams Pear

Heart: Sweet Pea

Base: White Musk

‘I can’t help but smile when I wear English Pear & Sweet Pea. It’s playful, subtle, and instantly makes my day better’—Lizzy Jagger

About Jo Malone London: Since 1994 Jo Malone London has created a palette of exquisitely simple, elegant scents and curated a world where every sense is indulged. Acquired by The Estée Lauder Companies Inc. in 1999, today the brand is internationally known for its unexpected fragrances and distinctly British character. Discover these new products alongside the full collection from March 2026, online and in-store. Follow Jo Malone London on TikTok, Instagram, Facebook, X, YouTube, LinkedIn and Pinterest @JoMaloneLondon #EnglishPear

US BioTek Laboratories Completes Merger With NutriPATH Pathology

By
Advertorial Desk
-

SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ — US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology laboratory serving integrative and functional medicine practitioners.

The merger marks a significant milestone for the global functional laboratory industry. It brings together the two organizations’ specialized expertise and a shared commitment to clinical relevance, scientific rigor, and practitioner support. The partnership expands both companies’ international footprint while enhancing access to comprehensive, clinically actionable testing for healthcare providers worldwide.

US BioTek Laboratories brings decades of experience in immune reactivity, food sensitivity, and specialty biomarker testing, while NutriPATH Pathology is recognized for its expertise in functional pathology, nutritional assessment, and gut health diagnostics. Together, the organizations will offer an expanded portfolio of testing solutions designed to support personalized, root-cause-focused care.

Jack Frausing, CEO of US BioTek Laboratories, commented,

“This merger marks an exciting new chapter for both US BioTek and NutriPATH. Our shared philosophy centers on providing clinicians with meaningful data they can trust and apply in practice. By bringing our teams and capabilities together, we are strengthening our ability to support practitioners with deeper insights, improved access, and expanded innovation.”

James Cavaggion, CEO of NutriPATH, alongside Directors Mary Cavaggion and Andrew Cavaggion, shared:

“This is more than a combination of two companies — it is a strategic alignment of values, scientific expertise, and a mutual dedication to advancing functional medicine globally.”

NutriPATH Pathology will continue to operate with its established brand presence in Australia, maintaining continuity for practitioners while gaining access to expanded resources, technologies, and collaborative scientific development. Clients of both organizations can expect a seamless transition and ongoing commitment to service excellence.

About US BioTek Laboratories

US BioTek Laboratories is a leading functional laboratory dedicated to delivering advanced immunological and specialty testing to integrative, functional, and personalized healthcare providers. Known for its expertise in food sensitivity testing, immune markers, toxin testing, and clinically actionable reporting, US BioTek partners closely with practitioners to support data-driven, patient-centered care.

About NutriPATH Pathology

NutriPATH Pathology is a trusted functional pathology laboratory based in Australia, providing comprehensive testing solutions across gut health, nutritional status, hormones, and metabolic markers. NutriPATH is widely recognized for its practitioner education, clinical support, and commitment to advancing functional medicine diagnostics.

Logo – https://laotiantimes.com/wp-content/uploads/2026/03/us_biotek_laboratories_and_nutripath_logo.jpg 

Skyhawk Announces Australia’s Therapeutic Goods Administration Has Determined SKY-0515 for Huntington’s Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

By
Advertorial Desk
-

Australia’s Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk’s SKY-0515 orally-administered small molecule therapy for the treatment of Huntington’s disease meets TGA eligibility criteria for registration via the provisional approval pathway.

Skyhawk delivered its application for provisional approval to the TGA today.

More than 115 patients are now on trial with SKY-0515.

BOSTON, March 3, 2026 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces that Australia’s Therapeutic Goods Administration (TGA), responsible for the approval of the safety, quality, and efficacy of therapeutic goods, has determined that the Company’s SKY-0515 orally-administered small molecule therapy for the treatment of Huntington’s disease meets TGA eligibility criteria for registration via the provisional approval pathway.

Skyhawk Therapeutics, Inc. 'Phase 1 Part C patient cohort cUHDRS and its components at 3, 6 and 9 months for patients who received SKY-0515 continuously for 9 months, once a day, with the data at 4mg and 9mg pooled (n=17),' January 2026. Note: Error bars represent standard error of the mean; Propensity score weighting (n=325) was performed using Enroll-HD and TRACK-HD.
Skyhawk Therapeutics, Inc. ‘Phase 1 Part C patient cohort cUHDRS and its components at 3, 6 and 9 months for patients who received SKY-0515 continuously for 9 months, once a day, with the data at 4mg and 9mg pooled (n=17),’ January 2026. Note: Error bars represent standard error of the mean; Propensity score weighting (n=325) was performed using Enroll-HD and TRACK-HD.

Skyhawk delivered its application submission to the TGA for provisional approval today.

“We are grateful that the TGA has determined SKY-0515 for the treatment of Huntington’s disease meets its eligibility criteria for potential provisional approval,” said Bill Haney, Skyhawk’s CEO. “This represents an important first step toward what could be an accelerated path to approval in Australia and the world, offering the possibility of a disease modifying treatment for Huntington’s patients who urgently need therapies for this devastating disease.”

Treatment with SKY-0515 results in dose-dependent reductions of mHTT and PMS1, key drivers of Huntington’s disease pathology. SKY-0515 has demonstrated excellent central nervous system exposure and been generally safe and well tolerated.

Patients receiving SKY-0515 in the Phase 1C trial of SKY-0515 demonstrate mean Composite Unified Huntington’s Disease Rating Scale (cUHDRS) improvement from baseline. At nine months this improvement is +0.64 points in a pooled analysis, compared to expected worsening at nine months of cUHDRS in symptomatic patients of -0.73 points, based on propensity score weighting using Enroll-HD and TRACK-HD.

Huntington’s disease is a rare, inherited and ultimately fatal neurodegenerative disorder that affects hundreds of thousands of people worldwide, including more than 40,000 symptomatic patients in the United States and over 2,000 Australians.1,2 There are currently no approved disease-modifying treatments which slow or halt disease progression.2

SKY-0515 is a small molecule RNA splicing modifier developed through Skyhawk’s novel RNA-splicing platform, SKYSTAR®.

SKY-0515 is the first Skyhawk drug in clinical trials.

Skyhawk is developing additional novel drugs to treat neurological diseases for which there are no approved disease-modifying therapies.

About SKY-0515’s Phase 1 Clinical Study
SKY-0515’s Phase 1 clinical trial is a first-in-human trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and individuals with Huntington’s disease (HD). The trial is separated into three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a double-blind placebo-controlled parallel design study of two dose levels of SKY-0515 and placebo in individuals with HD (HD-ISS Stage 1, 2, or mild Stage 3) for 84 days followed by a 12 month extension of active treatment where all participants receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study include evaluating mutant HTT protein and PMS1 mRNA. The first patients were dosed in SKY-0515’s Part C in January 2025. Enrollment in Phase 1C of the SKY-0515 trial is now complete and the trial is ongoing.

About SKY-0515’s Phase 2/3 FALCON-HD Clinical Study
FALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in 120 participants with Stage 2 and early Stage 3 HD across 12 sites in Australia and New Zealand, and 400 participants with Stage 2 and early Stage 3 HD in 40+ worldwide sites. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels or placebo, for a treatment period of at least 12 months. This trial aims to confirm the potential of SKY-0515 to modulate RNA splicing and reduce mHTT and PMS1 proteins, which are implicated in the pathology of Huntington’s disease, and to assess the efficacy of the SKY-0515 in affecting the rate of Huntington’s disease progression. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company which uses its proprietary platform, SKYSTAR®, to discover and develop small molecule RNA modulating therapies for the world’s most intractable diseases. For more information visit www.skyhawktx.com.

Skyhawk Contact
Maura McCarthy
Head of Corporate Development
maura@skyhawktx.com

References

  1. Australian Institute of Health and Welfare (AIHW) 2025, Huntington’s disease in Australia, viewed 8 February 2026, https://www.aihw.gov.au/reports/neurological-conditions/huntingtons-disease-in-australia
  2. Huntington’s Disease Society of America (HDSA) 2026, Overview of Huntington’s Disease, viewed 8 February 2026, https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/

Photo – https://laotiantimes.com/wp-content/uploads/2026/03/skyhawk_therapeutics__phase_1_part_c_patient_cohort_cuhdrs.jpg 

Puget Sound Energy Customers Can Earn Cash for Sharing Battery Power as FranklinWH Joins Flex Batteries Program

By
Advertorial Desk
-

Participants receive up to $1,000 for enrolling and ongoing payments when stored home energy is sent to the grid during peak demand to help avoid outages

SAN JOSE, Calif., March 3, 2026 /PRNewswire/ — FranklinWH Energy Storage Inc. (FranklinWH), a leader in whole-home energy management solutions, announced today its participation in Puget Sound Energy’s Flex Batteries program. The program encourages homeowners to enroll their home battery systems to support local grid reliability.

Through the Flex Batteries program, homeowners receive an enrollment incentive of up to $1,000 per battery, plus up to $500 per year for participating. When the grid is under strain, Puget Sound Energy (PSE) automatically pulls excess stored power from the system, and homeowners are paid for the energy their batteries provide. Events can be called year-round, helping prevent spikes on the power grid and reduce the need for less efficient sources of power while providing homeowners with direct financial benefits.

“With federal tax credits for home energy storage ending last year, programs such as this from Puget Sound Energy are an important way for homeowners to make battery backup affordable,” said Gary Lam, CEO and co-founder of FranklinWH. “This allows homeowners to keep their power on during outages, save on energy bills, and support the grid during high-demand periods.”

Lam said the program is a practical way for homeowners to maximize the value of their energy storage systems. “People want solutions that are simple, reliable, and worth their investment,” he said. “This program helps pay for an energy storage system that is more than backup power. It’s also a way to earn money from PSE while helping keep the power on across PSE’s territory.”

Batteries must be owned by PSE customers and interconnected with the PSE grid. Software technology providers Uplight and Derapi facilitate enrollment, battery dispatch, and customer payment. FranklinWH’s participation in Flex Batteries underscores the company’s commitment to saving homeowners money on energy costs, expanding access to clean energy incentives, and strengthening grid reliability across Washington and the United States.

About FranklinWH
FranklinWH Energy Storage manufactures the FranklinWH System, a next-generation home energy management and storage solution. Headquartered in the San Francisco Bay Area, FranklinWH combines decades of experience in energy system design, manufacturing, sales, and installation. The company is AVL-listed with multiple financial institutions and continues to help homeowners achieve energy freedom through reliable, integrated solar and battery systems. Learn more at www.franklinwh.com.

Contact: 
Media@franklinwh.com 

O’S BUBBLE & PINK ROCKET: WHEN SWEET MEETS SPICY, ‘SWICY’ A NEW CATEGORY IS BORN

By
Advertorial Desk
-

ANAHEIM, Calif., March 3, 2026 /PRNewswire/ — At a time when global palates are shifting toward layered, high-contrast flavors, two category leaders are choosing collaboration over competition.

This March at Natural Products Expo West, O’s Bubble and Pink Rocket will officially debut their first joint innovation — a ‘Swicy’ fusion concept that bridges beverage culture and Korean street food tradition.

O’s Bubble, the flagship brand under Orbitel International Group, has transformed bubble tea into a scalable global retail format, building its reputation on texture, comfort, and modern Asian lifestyle appeal.

Pink Rocket, a dynamic brand under Young Poong Co., Ltd., represents Korea’s fiery street-food heritage, engineered with manufacturing precision and global ambition.

Together, the two brands — each backed by their respective parent companies… introduce what they define as “Swicy,” a new flavor language where sweetness and heat coexist intentionally, not accidentally.

“We’ve spent years redefining how bubble tea lives beyond the café. This collaboration with Young Poong allows us to extend that thinking into new formats and flavor territories. Swicy isn’t just a pairing, it’s a flavor language we are defining and owning — a reflection of how modern consumers eat: layered, curious, and culturally fluid. And with topokki, Korea’s iconic comfort food, this partnership goes beyond export—we’re evolving a classic for what’s next.” said Fanny Chen, CEO, Orbitel International Group.

Introducing the Sweet & Spicy Hit
O’s Bubble approaches innovation from a different direction — reengineering bubble tea across frozen, microwaveable, and ready-to-enjoy formats. With deep understanding of North American consumers and strong retail execution, the brand has become an Amazon Best Seller in North America, demonstrating its ability to convert cultural flavor into scalable commercial success.

Orbitel International Group serves as the sole distributor of Young Poong’s Pink Rocket brand in the U.S. market, further strengthening the strategic bridge between the two companies.

Debuting at Expo West, the new co-developed concept blends creamy sweetness with calibrated Korean heat — layered with chew, sauce, and contrast. It draws inspiration from both bubble tea indulgence and Korean street-side spice culture.

The ‘Swicy’ collaboration will be featured at both the O’s Bubble booth and the Young Poong / Pink Rocket booth during Expo West 2026.

About Orbitel International Group
Orbitel International Group is a global food innovation company committed to bringing authentic Asian lifestyle products to the world. Its flagship brand O’s Bubble has redefined bubble tea — from frozen (BOBA 1.0) to microwaveable (BOBA 2.0) to its latest ready-to-eat Boba (BOBA 3.0). Operating in 50+ countries, Orbitel is trusted by retailers, distributors, and foodservice leaders for its supply chain excellence, product innovation, and strategic partnerships — all built on the belief that food and drink should always deliver Our Best Times. Learn more about us at https://orbitelinternational.com

Media Contact:
Ms. Nina Jen
Global Marketing, Orbitel International Group
nina@orbitel.com.tw

IFS Completes Acquisition of Softeon, Creating a Powerhouse in End-to-End Supply Chain Intelligence

By
Advertorial Desk
-

IFS Softeon unites Industrial AI and best-in-class warehouse management to deliver unified supply chain excellence from the boardroom to the warehouse floor

LONDON, March 3, 2026 /PRNewswire/ — IFS, the leading provider of Industrial AI software, today announced the completion of its acquisition of Softeon, providing enterprises across manufacturing, logistics and retail access to a new category of supply chain technology. Operating as IFS Softeon, the move brings together IFS’s powerful Industrial AI capabilities with Softeon’s 20+ years of tier-1 warehouse management software (WMS) expertise.

The launch of IFS Softeon marks a defining moment for the supply chain technology landscape, addressing a significant challenge – most enterprises run disconnected ERP and WMS systems, creating costly blind spots. IFS Softeon delivers what no other vendor can match: unified visibility from the boardroom to the warehouse floor, powered by Industrial AI – providing deep industrial domain knowledge, robotics orchestration and proven warehouse execution into a single, seamless offering.

IFS Softeon meets growing demand for integrated, intelligent supply chain solutions. IFS already manages $2.4T in critical assets and brings its industry-leading IFS Cloud platform, purpose-built for asset-intensive industries, alongside embedded Industrial AI capabilities and robotics orchestration expertise. IFS Softeon contributes a field-tested WMS platform, Gartner Visionary recognition*, and manages warehouse operations for a blue-chip customer base that includes Brooks, Casey’s, Denso, Sears Home Service, Sony, and UPS.  Together, IFS Softeon is processing millions of orders per month and managing warehouse operations across 30 countries.

Mark Moffat, CEO of IFS, commented: “The introduction of IFS Softeon means every enterprise wrestling with the complexity of modern supply chains now has access to something genuinely new: end-to-end supply chain intelligence, from strategic decision-making to physical execution on the warehouse floor. Industrial AI meets limitless warehouse execution. That’s a combination that will supercharge what’s possible for our customers.”

Jim Hoefflin, CEO, IFS Softeon, added: “Joining IFS is the natural next step in Softeon’s journey. Our customers chose us because we deliver. Now, backed by IFS’s Industrial AI platform and global reach, we can deliver even more – AI-driven warehouse orchestration, robotics interoperability, and predictive inventory intelligence. The future of warehouse management just got a whole lot more exciting.”

With a shared commitment to operational excellence and customer outcomes, the combined business will accelerate innovation across warehouse automation, inventory optimization and supply chain resilience. Existing Softeon customers will see continued investment and no disruption; existing IFS customers gain access to best-in-class WMS; and new prospects now have the choice of a single vendor for end-to-end supply chain intelligence.

*”Magic Quadrant for Warehouse Management Systems”, Simon Tunstall, Dwight Klappich, Rishabh Narang, Federica Stufano, 1 May 2025

CONTACT:

IFS Press Contacts:

EUROPE / MEA / APJ: Adam Gillbe
IFS, Director of Corporate & Executive Communications
Email: adam.gillbe@ifs.com

NORTH AMERICA / LATAM: Mairi Morgan
IFS, Director of Corporate & Executive Communications
Email: mairi.morgan@ifs.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Visa and Global Fashion Agenda Back Emerging Designers with Circular Fashion Programme

By
Advertorial Desk
-

COPENHAGEN, Denmark, March 3, 2026 /PRNewswire/ — Global Fashion Agenda (GFA) and Visa have launched Visa Young Creators: Recycle the Runway, a programme celebrating and empowering emerging designers to reimagine fashion through innovative circular design. An expert jury joins the programme to review and shortlist applications alongside the official Recycle the Runway Ambassador, Author and Podcaster, Gemma Styles.

Powered by Visa and GFA, the initiative aims to support the transition to a circular fashion system by backing the next wave of creative entrepreneurs who are paving the way to a more regenerative fashion economy. The programme seeks to spotlight creators and their businesses while embracing circular business practices, with finalists receiving financial support and mentorship.

The programme will select 15 winners in total. Ten winners will receive a share of EUR 50,000 to invest in their businesses. Four winners will each receive EUR 10,000, an invitation to participate in Global Fashion Summit: Copenhagen Edition 2026, individual pairing with leading solution providers to co-create a product, as well as expert mentorship sessions, promotional opportunities, and industry recognition. One Grand Prize Winner will receive EUR 20,000 to invest in their business, in addition to the aforementioned rewards. 

Applications will be shortlisted and reviewed by an esteemed jury of industry experts, including: Laura Ingham, Deputy Director, Global Fashion Network, Vogue; Kirsty Keoghan, General Manager, European Fashion, eBay; Shailja Dubé, Deputy Director, Institute of Positive Fashion, British Fashion Council; Philip Konopik, Group Country Manager, Nordics and Baltics, Visa Europe. The programme’s ambassador, Gemma Styles, will also serve as a jury member and support the initiative’s mission to spotlight and elevate emerging purpose-led talent.

Federica Marchionni, CEO, Global Fashion Agenda, said: “Through Recycle the Runway, we are proud to support the next generation of creators who are reimagining how fashion is designed, produced, and experienced. This initiative helps turn circular ideas into viable businesses that can shape a more regenerative future for fashion. By connecting creative talent with funding, mentorship, and industry platforms, GFA keeps accelerating the transition towards a more circular fashion system.”

Philip Konopik, Group Country Manager, Nordics and Baltics, Visa Europe, said: “At Visa, we help creators and small business thrive in a circular, digital-first world by pairing secure, seamless payments and commerce solutions with the education, resources and mentorship to turn bold ideas into scalable businesses to help drive sustainable economic growth. Through Visa Young Creators: Recycle the Runway with Global Fashion Agenda, we’re proud to empower the next generation of creators and spotlight how those purpose-led small businesses can speed the shift to a more regenerative fashion economy.” 

The programme is open to creators working in fashion upcycling, textiles, accessories or footwear, and apparel, who have been registered as a business owner for at least one year. Applicants must be headquartered in Europe, operate primarily within Europe, and run businesses aligned with circular activities including resell, repair, rental, refill, return, and redistribute. Shortlisted applicants must be available to attend Global Fashion Summit on 6–7 May 2026 in Copenhagen. View the full Terms & Conditions here.

View more information and application details here. Applications close on 7 March 2026.

CONTACT: 
For more information contact:
press@globalfashionagenda.org 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/global-fashion-agenda/r/visa-and-global-fashion-agenda-back-emerging-designers-with-circular-fashion-programme,c4313626

The following files are available for download:

Innovaccer Receives Frost & Sullivan’s 2026 United States New Product Innovation Recognition for Excellence in AI-Driven Patient Access Solutions

By
Advertorial Desk
-

The recognition highlights Innovaccer’s innovation leadership in transforming patient access through omnichannel, AI-powered engagement and workflow unification.

SAN ANTONIO, March 3, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Innovaccer has received the 2026 United States New Product Innovation Recognition in the United States Patient Access Solutions Industry for its outstanding achievements in innovation, strategy execution, and customer impact. This recognition highlights Innovaccer’s consistent leadership in modernizing patient access through AI-driven, omnichannel engagement, strengthening its market position, and delivering customer-centric innovation in an increasingly competitive healthcare landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Innovaccer excelled in both, demonstrating its ability to align strategic initiatives with evolving market demand while executing them with efficiency, consistency, and scale. “Frost & Sullivan recognizes Innovaccer for its innovative approach to patient access and engagement, highlighting its ability to unify fragmented workflows and deliver a truly omnichannel, AI-driven experience. The company’s Comet AI platform, a combination of autonomous AI agents and intelligent copilots, enhances operational efficiency, improves patient satisfaction, and boosts staff productivity,” said Alejandra Parra, Research Analyst at Frost & Sullivan.

Guided by a long-term growth strategy focused on digital innovation, data integration, and customer-centric partnerships, Innovaccer has demonstrated strong strategic agility in addressing critical gaps across the patient access value chain. The company’s sustained investment in artificial intelligence, automation, and healthcare interoperability has enabled it to scale effectively across the United States healthcare market, helping providers compress complex workflows and deliver more seamless care experiences.

Innovation remains central to Innovaccer’s approach. Comet AI™, the company’s patient access and engagement platform transforms traditional call centers into intelligent, always-on digital front doors that operate across voice, chat, SMS, and web channels. By unifying electronic medical records, scheduling, referral management, and communication tools into a single pane of glass, Comet AI enables healthcare staff to manage up to 70% to 80% of routine interactions autonomously while reserving human expertise for more complex cases.

 “Patient access is where healthcare systems feel the most pressure, high volumes, fragmented workflows, and rising expectations from patients,” said Abhinav Shashank, cofounder and CEO of Innovaccer. “Comet AI was built to address this reality by autonomously handling routine interactions across channels, unifying access workflows, and helping care teams operate with far greater speed and clarity. This recognition from Frost & Sullivan reinforces our belief that autonomous, AI-driven patient access is not a future concept and it is already delivering measurable impact for healthcare organizations today.” 

Innovaccer’s unwavering commitment to customer experience further strengthens its leadership in the patient access solutions market. The platform streamlines service delivery, enables self-service through intuitive digital channels, and maintains high levels of reliability and availability. AI copilots support live agents with next-best-action recommendations, real-time documentation, and insurance or eligibility verification, improving productivity while reducing burnout. This integrated, omnichannel model delivers measurable outcomes, including improved appointment bookings, reduced referral leakage, higher patient satisfaction, and demonstrable return on investment for healthcare organizations.

Frost & Sullivan commends Innovaccer for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s innovation pipeline, AI-driven vision, and patient-first culture are shaping the future of the United States patient access solutions industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the New Product Innovation Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The accolade recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Lindsey Whitaker
Lindsey.Whitaker@Frost.com

About Innovaccer

Innovaccer is the AI infrastructure for autonomous healthcare operations, delivering better clinical and financial outcomes across health systems, payers, governments, and life sciences. Powered by the Healthcare Intelligence Platform, Innovaccer unifies enterprise data and applies AI to automate administrative work, strengthen operational performance, and drive measurable margin expansion. Organizations such as Orlando Health, Adventist HealthCare, and Banner Health trust Innovaccer to integrate intelligence into their existing infrastructure and elevate the quality of care. For more information, visit www.innovaccer.com.

Press Contact:
Arushi Awasthi
Innovaccer Inc.
arushi.awasthi@innovaccer.com

1...874875876...6,442Page 875 of 6,442